Search Results

JACC White Paper Considers PCI for ULMCA

October 13, 2009—In the Journal of the American College of Cardiology (JACC), David E. Kandzari, MD, et al on behalf of the American College of Cardiology Interventional Scientific Council have published a JACC white paper, “Revascularization for Unprotected Left Main Disease: Evolution of the Evidence Basis to Redefine Treatment Standards” (2009;54:1576-1588).

Initial Findings Published From United States Postapproval Study for Boston Scientific's Promus Element Plus

December 11, 2015—David E. Kandzari, MD, et al published the first report of results from the PE-Plus Postapproval Study (PE-Plus PAS) online ahead of print in the American Journal of Cardiology. PE-Plus PAS was a prospective, open-label, multicenter, observational study designed to examine outcomes in everyday clinical practice among patients treated with Boston Scientific’s everolimus-eluting platinum chromium Promus Element stents at 52 centers in the United States.

No Increased Risk Seen in Stopping DAPT at 6 Months After Stenting

October 21, 2011—In the Journal of the American College of Cardiology: Cardiovascular Interventions, David E. Kandzari, MD, et al published findings from a study that sought to evaluate differences in late safety outcomes relative to dual-antiplatelet therapy (DAPT) duration in patients treated with zotarolimus-eluting stents (2011;4:1119–1128). The background of the study is that despite treatment recommendations for at least 12 months of DAPT following drug-eluting stent revascularization, device-specific outcomes relative to DAPT duration are absent, the investigators stated.

BIONICS Evaluates Safety and Efficacy of Medinol's Ridaforolimus-Eluting Stent

August 18, 2017—Primary results from the BIONICS trial were published online ahead of print by David E. Kandzari, MD, et al in Circulation. BIONICS was designed to determine the safety and efficacy of a ridaforolimus-eluting stent (RES) versus a slow-release zotarolimus-eluting stent (ZES).

Five-Year DESSOLVE Data Presented for Micell Technologies' MiStent

November 7, 2016—Micell Technologies, Inc. announced 5-year clinical safety and efficacy results from the DESSOLVE I and DESSOLVE II trials of the company’s MiStent sirolimus-eluting absorbable polymer coronary stent system.

Two-Year BIOFLOW-V Data Presented for Biotronik's Orsiro DES

September 24, 2018—Biotronik announced 2-year data from the BIOFLOW-V randomized trial at TCT 2018, the 30th annual Transcatheter Cardiovascular Therapeutics scientific symposium held September 21–25 in San Diego, California.

BIOFLOW-V 3-Year Data Presented for Biotronik’s Ultrathin-Strut Orsiro DES

February 24, 2020—Biotronik announced that 3-year data from the BIOFLOW-V trial were presented at CRT 2020, the Cardiovascular Research Technologies scientific conference held February 22–25 in National Harbor, Maryland.

EXPERT CTO Supports PCI for Highly Complex Lesions Using Contemporary Methods and EES

April 27, 2015—Results from the EXPERT CTO multicenter trial, which sought to evaluate procedural and clinical outcomes among patients undergoing chronic total occlusion (CTO) percutaneous coronary intervention (PCI) using contemporary methods and the Xience coronary everolimus-eluting stents (EES; Abbott Vascular), were published by David E. Kandzari, MD, et al online ahead of print in Journal of the American College of Cardiology (JACC): Cardiovascular Interventions. Specifically, EXPERT CTO evaluated the Xience Prime LL and Xience Nano EES.

One-Year Data Presented From BIOFLOW-V Pivotal Trial of Biotronik's Orsiro DES

August 28, 2017—Biotronik announced data from the BIOFLOW-V randomized trial comparing the company's Orsiro drug-eluting stent (DES) and the Xience DES (Abbott Vascular) for the primary endpoint noninferiority in 12-month target lesion failure (TLF).

Symplicity Spyral RDN Studied in Pooled Analyses From SPYRAL HTN Program

March 11, 2026—New analyses from the SPYRAL HTN clinical study program presented at CRT 2026 reported long-term outcomes with the Symplicity Spyral radiofrequency (RF) renal denervation (RDN) system (Medtronic), including a pooled 3-year efficacy analysis, a study of hypertensive urgencies, and the design of the SPYRAL CARE real-world study.

TARGET BP I RCT Investigates Ablative System’s Peregrine Alcohol-Based Renal Denervation System

April 8, 2024—Findings from the TARGET BP I pivotal phase 3 randomized clinical trial (RCT) of the Peregrine renal denervation system (Ablative Solutions) met its primary endpoint of lowering blood pressure at 3 months as measured with a 24-hour ambulatory systolic blood pressure monitor.

Two-Year BIONICS Data Presented for Medinol's EluNIR Stent

March 6, 2018—The EluNIR ridaforolimus-eluting coronary stent system (Medinol Ltd.; distributed by Cordis, a Cardinal Health company) continued to show comparable results to the Resolute zotarolimus-eluting stent (Medtronic) at 2-year follow-up, according to results presented at CRT 2018, the Cardiovascular Research Technologies conference held March 3–6 in Washington, DC.

Long-Term Data from DES Clinical Studies Published

June 1, 2011—Long-term follow-up data from three major clinical trials investigating drug-eluting stents have been published.

Five-Year DESSOLVE Data Published for Micell's MiStent

January 9, 2018—Micell Technologies, Inc. announced that a report of the 5-year data from the DESSOLVE I and DESSOLVE II trials by Professor William Wijn, MD, et al has been accepted for publication in EuroIntervention and is available online.

Initial Data Presented From SPYRAL HTN-ON MED Study of Medtronic's Symplicity Spyral Renal Denervation System

June 1, 2018—Medtronic recently announced first-ever data from the SPYRAL HTN-ON MED study.

CSI’s Propel Percutaneous Ventricular Assist Device Used in FIH Procedures

March 16, 2022—Cardiovascular Systems, Inc. (CSI) announced that the first-in-human procedures have been completed with the company’s first-generation Propel percutaneous ventricular assist device (pVAD).

Biotronik's Orsiro Coronary DES Approved in Japan

January 22, 2018—Biotronik announced market approval for its Orsiro coronary drug-eluting stent (DES) by the Japanese Ministry of Health.

CSI Announces FDA Clearance of the OrbusNeich 1-mm Sapphire II Pro Coronary Balloon

March 1, 2018—Cardiovascular Systems, Inc. (CSI) announced that the US Food and Drug Administration has granted 510(k) clearance for the company's OrbusNeich 1-mm Sapphire II Pro coronary balloon, which is designed for crossing and treating extremely tight and complex lesions.

Teleflex’s Ringer PBC Studied for Management of Coronary Perforations

March 31, 2025—Teleflex Incorporated announced preliminary results from its Ringer perfusion balloon catheter (PBC) investigational device exemption (IDE) study.